Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE Correction to: KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. 31172308 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE The aim of the current study was to assess the association of gastric cancer and KRAS mutation, demographic factors, and <i>H. pylori</i> infection. 31217933 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE This is the largest GC study investigating KRAS status and histological phenotype. 31111275 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE The CpG island methylator phenotype (CIMP), MLH1 methylation, TP53, and KRAS mutation statuses were characterized in 214 GCs in relation to their clinicopathological features and prognosis. 30575210 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Although KRAS mutations in GC are linked with MSI in the majority of cases, KRAS mutations with MSS status presented with a poor prognosis and a worse outcome. 29116623 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Overall, our results indicate that prolonged MAPK pathway inhibition could result in acquired resistance which is associated with increased malignant phenotype in KRAS mutant GC and pharmacological targeting c-MET and PI3K/mTOR could overcome this problem. 30466782 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE Gastric cancer (GC) is characterized by amplifications of receptor tyrosine kinases (RTK) and KRAS, therefore, targeting of the RTK/KRAS downstream pathways could help to broaden the applicability of molecular targeted therapy for GC. 27699948 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE MET-positive GCs were microsatellite stable and of KRAS/PIK3CA wild-type. 26033401 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE The MAPK pathway was activated by mutations and gene amplifications of ERBB2, FLT3, and KRAS in 11 GCs. 24510342 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE We assessed the mutational status of the entire KRAS coding sequence in 19 MSI-GC cases by multiplex PCR/sequencing and used peak height ratio determined from electropherograms from KRAS heterozygous mutants and histopathological evaluation to infer tumour heterogeneity in GC. 26318594 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth factor receptor, is currently considered to be the strategy with the most potential for the treatment of gastric cancer due to the low frequency of KRAS mutations in patients with gastric cancer. 25815786 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%). 25882375 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. 25086186 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE In summary, amplified PAK1, as well as KRAS amplification/mutation, may represent unique opportunities for developing targeted therapeutics for the treatment of gastric cancer. 24935174 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE The present study was to determine the role of KRAS status in EGFR antibody treatment for gastric cancer. 24467518 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Our data demonstrated that the T allele of the let-7 binding site polymorphism rs712 in KRAS 3' UTR was associated with a significantly increased risk of GC, suggesting that the KRAS rs712 polymorphism may be a genetic marker for the development of GC. 23729275 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE KRAS mutations were more frequent in MMR-deficient GC in the UK and the Japanese cohort (P<0.05). 23511561 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Integration of information on the genetic and epigenetic alterations revealed that the GCs with the CpG island methylator phenotype (CIMP) tended to have mutations of oncogenes, CTNNB1, ERBB2, KRAS, and PIK3CA. 23196062 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE We investigated the association of p53 and K-ras gene mutation and Helicobacter pylori infection in patients with gastric cancer (GC) and peptic ulcer disease (PUD) attending a tertiary care hospital in north India. 23168708 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE KRAS mutation was detected in one of the two instable gastric cancers, while none of the RCCs had KRAS mutations. 21687951 2011
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE These results support KRAS mutation may only be involved in carcinogenesis of partial gastric cancers and the different mutation types of KRAS may take part in development of gastric cancer at different stages. 19639197 2009
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 AlteredExpression disease BEFREE Our results suggest that the KRAS-MEK-ERK cascade has a positive regulatory role in GLI transcriptional activity in gastric cancer. 19142899 2009
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Amplification of the KRAS locus was detected in 15% (3/20) of gastric cancer cell lines (8-18-fold amplification) and 4.7% (4/86) of primary gastric tumors (8-50-fold amplification). 19545448 2009
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE In this review, we will discuss the involvement of E-cadherin, EGFR, ERBB2, MMR genes, KRAS, and PIK3CA in the development and progression of gastric cancer and their role as biomarkers or as novel putative targets for therapy. 19013893 2008
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE BRAF and KRAS mutations in stomach cancer. 14534542 2003